# Medical Coverage Policy | Cryosurgical Ablation of Primary or Metastatic Liver Tumors

**EFFECTIVE DATE:** 02|17|2015
**POLICY LAST REVIEWED:** 11|06|2024

## OVERVIEW
Cryosurgical ablation involves the freezing of target tissues, most often by inserting into the tumor a probe through which coolant is circulated. Cryosurgical ablation can be performed as an open surgical technique or percutaneously or laparoscopically, typically with ultrasound guidance.

## MEDICAL CRITERIA
Not applicable

## PRIOR AUTHORIZATION
Not applicable

## POLICY STATEMENT
**Medicare Advantage Plans**
Cryosurgical ablation of either primary or metastatic tumors in the liver is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

**Commercial Products**
Cryosurgical ablation of either primary or metastatic tumors in the liver is not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

## COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable not medically necessary benefits/not covered coverage.

## BACKGROUND
Cryosurgical ablation (CSA) involves the freezing of target tissues, often by inserting a probe through which coolant is circulated into the tumor. CSA can be performed as an open surgical technique or percutaneously or laparoscopically, typically with ultrasound guidance. For individuals who have unresectable primary hepatocellular carcinoma amenable to locoregional therapy who receive CSA, the evidence includes 1 randomized controlled trial (RCT), several nonrandomized comparative studies, and multiple noncomparative studies. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. The available RCT comparing cryoablation with radiofrequency ablation demonstrated lower rates of local tumor progression with cryoablation, but no differences in survival outcomes between groups. Although this trial provided suggestive evidence that cryoablation is comparable with radiofrequency ablation, trial limitations would suggest findings need to be replicated. Additional comparative evidence is needed to permit conclusions about the effectiveness of cryoablation compared with other locoregional therapies. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have unresectable liver metastases from neuroendocrine tumors amenable to locoregional therapy who receive CSA, the evidence includes a Cochrane review and case series. Relevant outcomes are overall survival, disease-specific survival, symptoms, and treatment-related mortality and morbidity. The available evidence base is very limited. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have unresectable liver metastases from colorectal cancer amenable to locoregional therapy who have CSA, the evidence includes 1 RCT, a number of nonrandomized comparative and

noncomparative studies, and systematic reviews of these studies. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. The available RCT comparing surgical resection with cryoablation was judged at high risk of bias. Some nonrandomized comparative studies have reported improved survival outcomes for patients managed with cryotherapy compared with those managed with resection alone; however, these studies were subject to bias in the selection of patients for treatments. Additional controlled studies are needed to permit conclusions about the effectiveness of cryoablation compared with other locoregional therapies. The evidence is insufficient to determine the effects of the technology on health outcomes.

## CODING

**Medicare Advantage Plans and Commercial Products**

The following CPT code(s) are not covered for Medicare Advantage Plans and not medically necessary Commercial Products:

**47371** Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical
**47381** Ablation, open, 1 or more liver tumor(s); cryosurgical
**47383** Ablation, 1 or more liver tumor(s), percutaneous, cryoablation

## RELATED POLICIES

None

## PUBLISHED

Provider Update, January 2025
Provider Update, January 2024
Provider Update, January 2023
Provider Update, December 2021
Provider Update, November 2020

## REFERENCES:


1.Singh SK, Singh R. Liver cancer incidence and mortality: Disparities based on age, ethnicity, health and nutrition,molecular factors, and geography. Cancer Health Disparities. Mar 2020; 4: e1-e10. PMID 34164612

2. Sohn RL, Carlin AM, Steffes C, et al. The extent of cryosurgery increases the complication rate after hepatic cryoablation.Am Surg. Apr 2003; 69(4): 317-22; discussion 322-3. PMID 12716090

3. Kim HI, An J, Han S, et al. Loco-regional therapies competing with radiofrequency ablation in potential indications forhepatocellular carcinoma : a network meta-analysis. Clin Mol Hepatol. Jul 05 2023. PMID 37403319

4. Keshavarz P, Raman SS. Comparison of combined transarterial chemoembolization and ablations in patients withhepatocellular carcinoma: a systematic review and meta-analysis. Abdom Radiol (NY). Mar 2022; 47(3): 1009-1023. PMID34982183

5. Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versusradiofrequency ablation in hepatocellular carcinoma. Hepatology. May 2015; 61(5): 1579-90. PMID 25284802

6. Wang Y, Li W, Man W, et al. Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACECombined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma. Comput Intell Neurosci. 2022; 2022:9783113. PMID 35795769

7. Luo J, Dong Z, Xie H, et al. Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellularcarcinoma: A prospective multicenter study. Liver Int. Apr 2022; 42(4): 918-929. PMID 35065003

8. Chen L, Ren Y, Sun T, et al. The efficacy of radiofrequency ablation versus cryoablation in the treatment of singlehepatocellular carcinoma: A population-based study. Cancer Med. Jun 2021; 10(11): 3715-3725. PMID 33960697

9. Cha SY, Kang TW, Min JH, et al. RF Ablation Versus Cryoablation for Small Perivascular Hepatocellular Carcinoma:Propensity Score Analyses of Mid-Term Outcomes. Cardiovasc Intervent Radiol. Mar 2020; 43(3): 434-444. PMID31844951

10. Ko SE, Lee MW, Rhim H, et al. Comparison of procedure-related complications between percutaneous cryoablation andradiofrequency ablation for treating periductal hepatocellular carcinoma. Int J Hyperthermia. Nov 17 2020; 37(1): 1354-1361. PMID 33297809
11. Wei J, Cui W, Fan W, et al. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization CombinedWith Microwave Ablation vs. Combined With Cryoablation. Front Oncol. 2020; 10: 1285. PMID 32850395
12. Ei S, Hibi T, Tanabe M, et al. Cryoablation provides superior local control of primary hepatocellular carcinomas of 2 cmcompared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. AnnSurg Oncol. Apr 2015; 22(4): 1294-300. PMID 25287439
13. Dunne RM, Shyn PB, Sung JC, et al. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: acomparison of the safety of cryoablation and radiofrequency ablation. Eur J Radiol. Apr 2014; 83(4): 632-8. PMID24529593
14. Awad T, Thorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database Syst Rev. Oct 07 2009; (4):CD007611. PMID 19821432
15. Ada R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency forunresectable hepatic malignancies. Arch Surg. Dec 2002; 137(12): 1332-9; discussion 1340. PMID 12470093
16. Yang Y, Wang C, Lu Y, et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellularcarcinoma. J Hepatobiliary Pancreat Sci. Nov 2012; 19(6): 674-84. PMID 22187145
17. Rong G, Bai W, Dong Z, et al. Long-term outcomes of percutaneous cryoablation for patients with hepatocellularcarcinoma within Milan criteria. PLoS One. 2015; 10(4): e0123065. PMID 25849963
18. Zhou L, Yang YP, Feng YY, et al. Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: apilot clinical study. Ai Zheng. Jan 2009; 28(1): 45-8. PMID 19448416
19. Wang C, Lu Y, Chen Y, et al. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma afterargon-helium cryoablation: a prospective study. Clin Exp Metastasis. 2009; 26(7): 839-48. PMID 19784786
20. Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors:safe hepatic surgery. World J Surg. Jun 2001; 25(6): 689-92. PMID 11376398
21. Gurusamy KS, Ramamoorthy R, Sharma D, et al. Liver resection versus other treatments for neuroendocrine tumours inpatients with resectable liver metastases. Cochrane Database Syst Rev. Apr 15 2009; (2): CD007060. PMID 19370671
22. Saxena A, Chua TC, Chu F, et al. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasmhepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol. Oct2012; 35(5): 439-45. PMID 21654315
23. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: aparadigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. Dec 2001; 130(6): 954-62. PMID11742323
24. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancerliver metastases. Cochrane Database Syst Rev. Apr 16 2008; (2): CD006039. PMID 18425932
25. Korpan NN. Hepatic cryosurgery for liver metastases. Long-term follow-up. Ann Surg. Feb 1997; 225(2): 193-201. PMID9065296
26. Bala MM, Riemsma RP, Wolff R, et al. Cryotherapy for liver metastases. Cochrane Database Syst Rev. Jun 05 2013; (6):CD009058. PMID 23740609
27. Gurusamy KS, Ramamoorthy R, Imber C, et al. Surgical resection versus non-surgical treatment for hepatic node positivepatients with colorectal liver metastases. Cochrane Database Syst Rev. Jan 20 2010; (1): CD006797. PMID 20091607
28. Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis.Sep 2011; 13(9): e252-65. PMID 21689362
29. Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectablecolorectal liver metastases: a prospective study. Ann Surg Oncol. Mar 2007; 14(3): 1161-9. PMID 17195903

30. Niu R, Yan TD, Zhu JC, et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy forliver metastases from colorectal carcinoma. Ann Surg Oncol. Jul 2007; 14(7): 2078-87. PMID 17473951
31. Joosten J, Jager G, Oyen W, et al. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases.Eur J Surg Oncol. Dec 2005; 31(10): 1152-9. PMID 16126363
32. Ng KM, Chua TC, Saxena A, et al. Two decades of experience with hepatic cryotherapy for advanced colorectalmetastases. Ann Surg Oncol. Apr 2012; 19(4): 1276-83. PMID 21913018
33. Seifert JK, Springer A, Baier P, et al. Liver resection or cryotherapy for colorectal liver metastases: a prospective casecontrol study. Int J Colorectal Dis. Nov 2005; 20(6): 507-20. PMID 15973545
34. Kornprat P, Jarnagin WR, DeMatteo RP, et al. Role of intraoperative thermoablation combined with resection in thetreatment of hepatic metastasis from colorectal cancer. Arch Surg. Nov 2007; 142(11): 1087-92. PMID 18025338
35. Xu KC, Niu LZ, He WB, et al. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World JGastroenterol. Mar 07 2008; 14(9): 1430-6. PMID 18322961
36. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: HepatocellularCarcinoma. Version 1.2023.
https://www.nccn.org/professionals/physician_gls/PDF/hcc.pdf. Accessed August 8, 2023.